X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1433) 1433
Publication (198) 198
Book Review (16) 16
Newsletter (15) 15
Newspaper Article (10) 10
Magazine Article (9) 9
Book Chapter (4) 4
Dissertation (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1081) 1081
mefloquine (901) 901
malaria (680) 680
male (638) 638
female (563) 563
index medicus (544) 544
adult (522) 522
animals (520) 520
antimalarials - therapeutic use (501) 501
antimalarials - administration & dosage (475) 475
malaria, falciparum - drug therapy (430) 430
mefloquine - administration & dosage (371) 371
tropical medicine (360) 360
mefloquine - therapeutic use (339) 339
drug therapy, combination (323) 323
adolescent (315) 315
infectious diseases (305) 305
plasmodium falciparum - drug effects (290) 290
drug resistance (287) 287
parasitology (279) 279
plasmodium falciparum (279) 279
middle aged (273) 273
child (269) 269
antimalarials - adverse effects (263) 263
parasitic diseases (240) 240
chloroquine (232) 232
artesunate (231) 231
research (229) 229
malaria - drug therapy (228) 228
drug therapy (224) 224
treatment outcome (224) 224
antimalarials - pharmacology (220) 220
antimalarials (217) 217
drug combinations (217) 217
pharmacology & pharmacy (213) 213
mefloquine - adverse effects (210) 210
malaria - prevention & control (204) 204
public, environmental & occupational health (201) 201
child, preschool (199) 199
artemisinins - therapeutic use (189) 189
thailand (185) 185
artemisinins - administration & dosage (182) 182
efficacy (179) 179
plasmodium-falciparum (165) 165
children (159) 159
artemisinin (158) 158
medicine, general & internal (154) 154
parasites (153) 153
plasmodium-falciparum malaria (153) 153
artemisinins (152) 152
health aspects (152) 152
antimalarials - pharmacokinetics (149) 149
infant (146) 146
mefloquine - pharmacology (144) 144
travel (143) 143
drugs (139) 139
pharmacokinetics (138) 138
administration, oral (137) 137
malaria, falciparum - parasitology (137) 137
mice (135) 135
sesquiterpenes - administration & dosage (135) 135
sesquiterpenes - therapeutic use (133) 133
dosage and administration (132) 132
microbiology (126) 126
pregnancy (123) 123
artemether (120) 120
infectious and parasitic diseases (116) 116
combination (112) 112
arctic medicine. tropical medicine (111) 111
resistance (110) 110
drug administration schedule (109) 109
artemether-lumefantrine (107) 107
young adult (107) 107
chloroquine - therapeutic use (106) 106
aged (103) 103
pyrimethamine - therapeutic use (101) 101
mefloquine - pharmacokinetics (96) 96
sulfadoxine - therapeutic use (96) 96
analysis (95) 95
malaria, falciparum - epidemiology (95) 95
quinine (95) 95
sulfadoxine-pyrimethamine (93) 93
drug dosages (92) 92
infections (90) 90
care and treatment (88) 88
public health (87) 87
pyrimethamine - administration & dosage (86) 86
prophylaxis (85) 85
risk factors (84) 84
sulfadoxine - administration & dosage (83) 83
immunology (82) 82
prevention (82) 82
time factors (82) 82
malaria, falciparum - prevention & control (81) 81
pyrimethamine (81) 81
vector-borne diseases (81) 81
dose-response relationship, drug (80) 80
chloroquine - administration & dosage (79) 79
artesunate-mefloquine (78) 78
medicine (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1378) 1378
French (40) 40
German (17) 17
Spanish (7) 7
Danish (5) 5
Portuguese (5) 5
Japanese (4) 4
Russian (4) 4
Hungarian (3) 3
Norwegian (3) 3
Dutch (2) 2
Italian (2) 2
Swedish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2018, Volume 2018, Issue 2, p. CD008152
Background The 8-aminoquinoline (8AQ) drugs act on Plasmodium falciparum gametocytes, which transmit malaria from infected people to mosquitoes. In 2012, the... 
45 MG PRIMAQUINE | ARTEMETHER-LUMEFANTRINE | SULFADOXINE-PYRIMETHAMINE | Artemisinins [administration & dosage; therapeutic use] | Quinine [therapeutic use] | Plasmodium falciparum [drug effects] | Malaria, Falciparum [parasitology; prevention & control; transmission] | LOW-DOSE PRIMAQUINE | GAMETOCYTOCIDAL ACTIVITY | Primaquine [administration & dosage] | Glucosephosphate Dehydrogenase Deficiency [diagnosis] | SPORONTOCIDAL TREATMENT | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Sulfadoxine [administration & dosage] | MALARIA CONTROL | DIHYDROARTEMISININ-PIPERAQUINE | THERAPEUTIC-EFFICACY | Pyrimethamine [administration & dosage] | ARTESUNATE-MEFLOQUINE | Antimalarials [administration & dosage] | Mefloquine [therapeutic use] | Drug Combinations | Chloroquine [therapeutic use] | Malaria, Falciparum - prevention & control | Humans | Artemisinins - administration & dosage | Sulfadoxine - administration & dosage | Chloroquine - therapeutic use | Plasmodium falciparum - drug effects | Primaquine - administration & dosage | Glucosephosphate Dehydrogenase Deficiency - diagnosis | Malaria, Falciparum - parasitology | Malaria, Falciparum - transmission | Quinine - therapeutic use | Primaquine - analogs & derivatives | Artemisinins - therapeutic use | Mefloquine - therapeutic use | Antimalarials - administration & dosage | Pyrimethamine - administration & dosage | Time Factors | Mefloquine - administration & dosage | Non-Randomized Controlled Trials as Topic | Adult | Chloroquine - administration & dosage | Child
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2012, Volume 161, Issue 3, pp. 735 - 745
The objective of the present study was to investigate the effect of polyarginine chain length on topical delivery of surface modified NLCs. Design of... 
Nanostructured lipid carriers (NLC) | Cell penetrating peptide (CPP) | Polyarginine peptide | Skin delivery | Allergic contact dermatitis (ACD) | DRUG-DELIVERY | CHITOSAN CROSS-LINKING | TRANSDERMAL DELIVERY | MEFLOQUINE HYDROCHLORIDE MICROPARTICLES | CELL-PENETRATING PEPTIDES | TACROLIMUS OINTMENT | CHEMISTRY, MULTIDISCIPLINARY | DERMAL DELIVERY | PHARMACOLOGY & PHARMACY | H-II MESOPHASES | SUBSTANCE-P | SPANTIDE-II | Nanoparticles - chemistry | Drug Carriers - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Drug Carriers - chemistry | Peptides - administration & dosage | Ketoprofen - chemistry | Allergens - administration & dosage | Lipids - chemistry | Rats, Hairless | Skin Absorption - drug effects | Substance P - analogs & derivatives | Oligopeptides - chemistry | Cell-Penetrating Peptides - chemistry | Dermatitis, Allergic Contact - drug therapy | Peptides - chemistry | Mice, Inbred C57BL | Ketoprofen - administration & dosage | Rats | Lipids - administration & dosage | Dinitrofluorobenzene - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Mice | Nanoparticles - administration & dosage | Oligopeptides - administration & dosage | Cell-Penetrating Peptides - administration & dosage | Administration, Topical | Substance P - chemistry | Substance P - administration & dosage | Usage | Peptides | Dermatology | Analysis | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Raman spectroscopy | Transdermal medication | polyarginine peptide | cell penetrating peptide (CPP) | nanostructured lipid carriers (NLC) | allergic contact dermatitis (ACD)
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2009, Volume 361, Issue 5, pp. 455 - 467
Journal Article
Malaria Journal, ISSN 1475-2875, 2007, Volume 6, Issue 1, pp. 80 - 80
Background: In view of the high level of chloroquine resistance in many countries, WHO has recommended the use of combination therapy with artemisinin... 
SULFADOXINE/PYRIMETHAMINE | BENFLUMETOL | SULFADOXINE-PYRIMETHAMINE | ARTEMETHER-LUMEFANTRINE | AMODIAQUINE | RANDOMIZED-TRIAL | MEFLOQUINE | ARTESUNATE | PARASITOLOGY | TROPICAL MEDICINE | CHILDREN | Ethanolamines - adverse effects | Follow-Up Studies | Humans | Middle Aged | Fluorenes - therapeutic use | Child, Preschool | Sulfadoxine - administration & dosage | Infant | Sesquiterpenes - administration & dosage | Sulfadoxine - adverse effects | Plasmodium falciparum - drug effects | Ethanolamines - administration & dosage | Sesquiterpenes - adverse effects | Sesquiterpenes - therapeutic use | Mefloquine - therapeutic use | Pyrimethamine - administration & dosage | Sulfadoxine - therapeutic use | Mefloquine - administration & dosage | Adult | Amodiaquine - adverse effects | Fluorenes - administration & dosage | Fluorenes - adverse effects | Amodiaquine - therapeutic use | Drug Therapy, Combination | Child | Drug Resistance | Pyrimethamine - therapeutic use | Antimalarials - adverse effects | Malaria, Falciparum - drug therapy | Pyrimethamine - adverse effects | Artemisinins - administration & dosage | Treatment Outcome | Antimalarials - therapeutic use | Amodiaquine - administration & dosage | Mefloquine - adverse effects | Animals | Artemisinins - therapeutic use | Antimalarials - administration & dosage | Senegal | Adolescent | Ethanolamines - therapeutic use | Aged | Artemisinins - adverse effects | Drug Combinations | Antimalarials | Evaluation | Dosage and administration | Drug therapy, Combination | Malaria | Drug therapy
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 12/2007, Volume 45, Issue 11, pp. 1453 - 1461
Background. Combination antimalarial therapy is advocated to improve treatment efficacy and limit selection of drug-resistant parasites. We compared the... 
Medical treatment failures | Relapse | Malaria | Vomiting | Articles and Commentaries | Antimalarials | Infections | Parasites | Parasitemia | Falciparum malaria | Fever | ANTIMALARIAL-DRUG | INFECTIOUS DISEASES | EFFICACY | COMBINATION THERAPY | MICROBIOLOGY | MEFLOQUINE | IMMUNOLOGY | CHLOROQUINE | CHILDREN | TRIAL | VIVAX MALARIA | TOLERABILITY | ARTESUNATE | Ethanolamines - adverse effects | Humans | Fluorenes - therapeutic use | Child, Preschool | Sulfadoxine - administration & dosage | Male | Sulfadoxine - adverse effects | Quinolines - administration & dosage | Ethanolamines - administration & dosage | Plasmodium falciparum | Pyrimethamine - administration & dosage | Sulfadoxine - therapeutic use | Amodiaquine - adverse effects | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Amodiaquine - therapeutic use | Drug Therapy, Combination | Child | Pyrimethamine - therapeutic use | Antimalarials - adverse effects | Malaria, Falciparum - drug therapy | Pyrimethamine - adverse effects | Artemisinins - administration & dosage | Antimalarials - therapeutic use | Amodiaquine - administration & dosage | Animals | Artemisinins - therapeutic use | Burkina Faso | Antimalarials - administration & dosage | Ethanolamines - therapeutic use | Quinolines - therapeutic use | Artemisinins - adverse effects | Drug Combinations | Quinolines - adverse effects | Demographic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Comparative analysis | Health aspects
Journal Article
Malaria Journal, ISSN 1475-2875, 2011, Volume 10, Issue 1, pp. 212 - 212
Background: Tafenoquine is an 8-aminoquinoline being developed for radical cure (blood and liver stage elimination) of Plasmodium vivax. During monotherapy... 
VIVAX MALARIA | RELAPSE | ANTIMALARIAL-DRUGS | WR-238605 | FALCIPARUM-MALARIA | PHARMACOKINETICS | CHLOROQUINE | PRIMAQUINE | PARASITOLOGY | TROPICAL MEDICINE | BLOOD | Quinine - pharmacokinetics | Artemisinins - pharmacokinetics | Humans | Aminoquinolines - administration & dosage | Male | Ethanolamines - administration & dosage | Ethanolamines - pharmacokinetics | Mass Spectrometry | Mefloquine - administration & dosage | Mefloquine - pharmacokinetics | Chromatography, Liquid | Fluorenes - administration & dosage | Plasmodium cynomolgi | Disease Models, Animal | Fluorenes - pharmacokinetics | Antimalarials - pharmacokinetics | Artemisinins - administration & dosage | Treatment Outcome | Macaca mulatta - parasitology | Drug Therapy, Combination - methods | Animals | Antimalarials - administration & dosage | Plasma - chemistry | Primate Diseases - drug therapy | Quinine - administration & dosage | Chloroquine - administration & dosage | Aminoquinolines - pharmacokinetics | Malaria - drug therapy | Chloroquine - pharmacokinetics | Drug Combinations | Tafenoquine | Complications and side effects | Plasmodium | Malaria | Causes of | Physiological aspects | Dosage and administration | Research | Drug therapy | Drugs | Phosphates | Mefloquine | Toxicity | Liver | Chloroquine | Cohorts | Parasites | Monkeys & apes | Quinine | Blood | Fever | Glucose dehydrogenase | Armed forces | Artemether | Laboratory animals | Glucosephosphate dehydrogenase | Drug dosages | Public health
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2015, Volume 2015, Issue 2, p. CD008152
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, p. CD008152
Journal Article
The Lancet, ISSN 0140-6736, 2004, Volume 364, Issue 9432, pp. 438 - 447
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10012, pp. 2507 - 2519
Journal Article
Journal Article